Mentioned in ?
References in periodicals archive ?
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: A double-blind, randomised, dose-escalation phase 1/2 trial.
A novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi Sensu Lato.
Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State.
Evaluation of the C6 peptide enzyme-linked immunosorbent assay www.mlo-online.com for individuals vaccinated with the recombinant OspA vaccine. J.